TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24247188
Drug: Pycnogenol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol 150 mg/day
Study: 26088659
Drug: No pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacotherapy
Study: 21661618
Drug: With pharmacotherapy
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: With pharmacotherapy
Study: 19704167
Drug: Untreated (treatment-naive)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated (treatment-naive) group
Study: 14572305
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of intravenous magnesium sulphate (treatment trial)
Study: 11262213
Drug: hPIV3 maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hPIV3 maternal antibody
Study: 9151912
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with epirubicin (40 mg/m2 intra-arterial at 1 month after resection, followed by intravenous administration of 40 mg/m2 every 3 months for 2 years) and carmofur (300 mg/d orally for 24 months)
Study: 28789663
Drug: Sodium nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitrate treatment
Study: 26536702
Drug: Golden voice
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golden voice capsule
Study: 26536702
Drug: Golden voice
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golden voice capsule and omeprazole
Study: 24011069
Drug: LY2405319 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2405319 (3, 10, or 20 mg daily for 28 days)
Study: 12167446
Drug: Droperidol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1.25 mg)
Study: 10769552
Drug: 20 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ppm inhaled nitric oxide
Study: 8885949
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without inhaled nitric oxide
Study: 1570886
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 0.5% bupivacaine/median approach
Study: 1570886
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml 0.5% bupivacaine/paramedian approach
Study: 26844723
Drug: Normal-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose therapy (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily)
Study: 26844723
Drug: Low-dose therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose therapy (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily)
Study: 26844723
Drug: Normal-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose therapy
Study: 26844723
Drug: Low-dose therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose therapy
Study: 26844723
Drug: Low-dose and
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose and normal-dose groups
Study: 24649831
Drug: 6 weekly
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weekly educational sessions promoting healthful nutrition and physical activity
Study: 20613476
Drug: Cosyntropin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosyntropin (1 mg intravenously)
Study: 17625622
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop with Z2000 (3M Espe)
Study: 15702438
Drug: Regular pulsatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular pulsatile insulin release pattern
Study: 15702438
Drug: Irregular pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular pulse frequency insulin release pattern
Study: 15702438
Drug: Irregular pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular pulse amplitude insulin release pattern
Study: 15702438
Drug: Very fast-pulsatile
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very fast-pulsatile insulin release pattern
Study: 15702438
Drug: Constant insulin
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant insulin infusion
Study: 12083474
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered lorazepam before surgery
Study: 778989
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (4.55 g daily)
Study: 778989
Drug: Micro-encapsulated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-encapsulated aspirin (4.50 g daily)
Study: 778989
Drug: Micro-encapsulated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-encapsulated aspirin
Study: 778989
Drug: Both aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both aspirin preparations
Study: 24657236
Drug: Omalizumab 600
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 600 mg
Study: 23432142
Drug: Omalizumab 75
Normalized name: OMALIZUMAB 75MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 75 mg
Study: 19668245
Drug: Mood-stabilizing drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood-stabilizing drug or neuroleptic in severe cases
Study: 19668245
Drug: Lithium or
Normalized name: Lithium Orotate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium or anticonvulsant for prophylaxis
Study: 9507989
Drug: Low DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low DHA (0.75 g/day)
Study: 9507989
Drug: High DHA
Normalized name: Fish Oil/Stevia Extract 850 MG-10 MG Oral Packet [COROMEGA CHILD BRAIN & BODY HIGH DHA OMEGA-3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High DHA (1.50 g/day)
Study: 12365829
Drug: Ancrod treatment
Normalized name: ancrod
DrugBank: Ancrod (DB05099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancrod treatment
Study: 30257549
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks, increased to 150 mg if LDL-C ≥ 70 mg/dL at week 8)
Study: 31802485
Drug: Erythromycin infusion
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin infusion
Study: 17726361
Drug: Multidimensional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional training program including moderate resistance exercise and balance exercise twice weekly for 6 months
Study: 11808868
Drug: Thiocolchicoside, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiocolchicoside, 4 mg ampoules (test formulation)
Study: 11808868
Drug: Muscoril, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscoril, 4 mg ampoules (reference formulation)
Study: 23349486
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment for 10 days
Study: 23349486
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment for 21 days
Study: 19928571
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid and emoxypine during the first 10 days of standard chemotherapy
Study: 16987112
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) withdrawal for 3 months
Study: 8439024
Drug: 25 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms/kg intravenous alfentanil
Study: 8439024
Drug: 50 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/kg intravenous alfentanil
Study: 3730521
Drug: Intravenous bromopride
Normalized name: bromopride
DrugBank: Bromopride (DB09018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bromopride 10 mg
Study: 3730521
Drug: Oral bromopride
Normalized name: bromopride
DrugBank: Bromopride (DB09018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromopride 20 mg
Study: 3730521
Drug: Intramuscular bromopride
Normalized name: bromopride
DrugBank: Bromopride (DB09018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular bromopride 20 mg
Study: 3730521
Drug: Oral bromopride
Normalized name: bromopride
DrugBank: Bromopride (DB09018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromopride 10 mg
Study: 3730521
Drug: Oral bromopride
Normalized name: bromopride
DrugBank: Bromopride (DB09018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromopride 30 mg
Study: 30221595
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of enteric-coated aspirin
Study: 20091934
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of epidural local anesthetics plus intravenous opioids
Study: 20091934
Drug: Intravenous opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioids only
Study: 16157797
Drug: 2% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dorzolamide 3 times daily
Study: 16157797
Drug: 0.25% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% timolol maleate gel-forming solution once daily plus placebo twice daily (control)
Study: 7570396
Drug: Therapeutic treatment
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic treatment
Study: 444661
Drug: BCMP (melphalan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMP (melphalan, cyclophosphamide, and carmustine) with tapering course of prednisone
Study: 444661
Drug: MP (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP (oral melphalan) with tapering course of prednisone
Study: 30557108
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shockwave therapy (ESWT) with standard care
Study: 30557108
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with standard care
Study: 25339110
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stents (Resolute zotarolimus-eluting or Xience V everolimus-eluting stents)
Study: 17679749
Drug: Gabapentin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (400 mg) administered twice weekly after HD sessions for four weeks
Study: 17679749
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice weekly after HD sessions for four weeks
Study: 11514042
Drug: Inhaled glucocorticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticosteroid (Pulmicort Turbuhaler)
Study: 7621843
Drug: Bambuterol 20
Normalized name: bambuterol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 20 mg nocte
Study: 3125773
Drug: Intermittent rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent rectal diazepam
Study: 3125773
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral sodium valproate
Study: 29525281
Drug: LetiFend® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LetiFend® vaccine
Study: 27397444
Drug: Oral Vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vitamin C (500 mg) twice daily for 7 days prior to surgery
Study: 27397444
Drug: Antacid tablet
Normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid tablet as placebo twice daily for 7 days prior to surgery
Study: 27397444
Drug: Antacid tablet
Normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid tablet as placebo
Study: 27397444
Drug: Oral Vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vitamin C (500 mg)
Study: 20117571
Drug: Micro intervention
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro intervention (monthly home visits by a promotora over a 7-month period plus monthly mailed newsletters)
Study: 12462550
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT)
Study: 7485045
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) with Lovastatin
Study: 7011597
Drug: Intravenous LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous LHRH (100 micrograms)
Study: 18193496
Drug: missing at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: missing at least 1 medication dose ever
Study: 18193496
Drug: missing at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: missing at least 1 medication dose in the past month
Study: 18193496
Drug: missing at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: missing at least 1 medication dose in the past weekend
Study: 15134179
Drug: Long ZDV
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long ZDV treatment duration for mothers (more than 7.5 weeks)
Study: 15134179
Drug: Short ZDV
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short ZDV treatment duration for mothers (no more than 7.5 weeks)
Study: 15134179
Drug: Long ZDV
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received short treatment
Study: 15134179
Drug: Short ZDV
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short ZDV treatment duration for infants (3 days) when mothers received short treatment
Study: 15134179
Drug: Long ZDV
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received long treatment
Study: 11402637
Drug: Heat plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat plus patch (5 mg androgen patch with heat-generating patch)
Study: 11402637
Drug: Patch only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch only (5 mg androgen patch without heat)
Study: 11402637
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch (no testosterone patch)
Study: 3907331
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg bid
Study: 3907331
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg hs
Study: 3907331
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg hs
Study: 3907331
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg bid
Study: 3907331
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg hs
Study: 10929897
Drug: IgA antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA antibodies
Study: 4202264
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies
Study: 29627147
Drug: Neutralising antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralising antibodies
Study: 31600715
Drug: Tourniquet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tourniquet plus intravenous tranexamic acid
Study: 19811918
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + oral cyclophosphamide (RT+C)
Study: 11123828
Drug: Penicillin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (two or more doses)
Study: 11123828
Drug: Penicillin (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (one or fewer doses)
Study: 11123828
Drug: Penicillin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (two doses)
Study: 11123828
Drug: Penicillin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (three doses)
Study: 8761138
Drug: 20 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/d of PEG 4000 without electrolyte addition
Study: 2862081
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg prostaglandin E2 (PGE2)
Study: 2862081
Drug: gel only
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel only
Study: 24706842
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) for 6 months
Study: 29025631
Drug: No isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No isoniazid preventive therapy (no IPT)
Study: 12369756
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of glimepiride (1.0 mg)
Study: 3479527
Drug: Oxiracetam 800
Normalized name: oxiracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam 800 mg bid
Study: 25480348
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2 g/day plus alfacalcidol 1 μg
Study: 22546009
Drug: Other artemisinin-based
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other artemisinin-based combination therapies (ACT)
Study: 22546009
Drug: Both G6PD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both G6PD deficiency and CDA treatment
Study: 20722560
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of dialysis treatments
Study: 18222001
Drug: Conservative ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative ocular therapies and chemothermotherapy (intravenous carboplatin followed by transpupillary thermotherapy) after chemoreduction by 2 cycles of carboplatin and etoposide
Study: 18222001
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (2 cycles of carboplatin and etoposide) followed by ocular therapy and chemothermotherapy
Study: 18222001
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with ocular therapy and chemothermotherapy
Study: 16152837
Drug: Pifubing Xuedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pifubing Xuedu Pill (PXDP) combined with Diyin Tablet (DYT)
Study: 12577369
Drug: Diyin Tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diyin Tablet (DYT) alone
Study: 12063530
Drug: Injected heparin
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected heparin
Study: 11928567
Drug: Inhaled heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled heparin
Study: 9987495
Drug: Regional chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional chemotherapy (historical control trials)
Study: 7838635
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume feeding (10 mL/kg)
Study: 1978770
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg/d
Study: 3105558
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg/d
Study: 639831
Drug: Norethindrone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone (5 to 20 mg single oral doses)
Study: 2561379
Drug: Intramuscular ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ACTH
Study: 28829884
Drug: Oral Prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Prednisolone
Study: 23281706
Drug: Melatonin 0.3
Normalized name: melatonin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.3 mg·kg(‐1)
Study: 23281706
Drug: Clonidine 4
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 4 μg·kg(‐1)
Study: 22332395
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon 2 in the form of suppositories (genferon and viferon)
Study: 9695162
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pseudoephedrine
Study: 8385564
Drug: Amonafide (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amonafide (1600 mg/m2, 24-hour continuous infusion every 21 days)
Study: 8385564
Drug: Trimetrexate (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetrexate (150 mg/m2, intravenous over 30 minutes every 2 weeks)
Study: 3083793
Drug: Prostacyclin infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin infusion, 50 ng per kilogram of body weight per minute during cardiopulmonary bypass (CPB)
Study: 29626232
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g WP
Study: 29626232
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g WP
Study: 29626232
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g WP (placebo)
Study: 25173357
Drug: Renal scan
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal scan at 12 months (Antibiotic group)
Study: 19236691
Drug: 10 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 week programme of supervised aerobic exercises (twice weekly) and individually tailored brief intervention lifestyle counselling